142 related articles for article (PubMed ID: 38287266)
1. Prognostic marker CXCL5 in glioblastoma polyformis and its mechanism of immune invasion.
Yu W; Zhou M; Niu H; Li J; Li Q; Xu X; Liang F; Rui C
BMC Cancer; 2024 Jan; 24(1):140. PubMed ID: 38287266
[TBL] [Abstract][Full Text] [Related]
2. CXCL5 promotes tumorigenesis and angiogenesis of glioblastoma via JAK-STAT/NF-κb signaling pathways.
Mao P; Wang T; Du CW; Yu X; Wang MD
Mol Biol Rep; 2023 Oct; 50(10):8015-8023. PubMed ID: 37541997
[TBL] [Abstract][Full Text] [Related]
3. Construction of an immune-related gene signature for the prognosis and diagnosis of glioblastoma multiforme.
Yu Z; Yang H; Song K; Fu P; Shen J; Xu M; Xu H
Front Oncol; 2022; 12():938679. PubMed ID: 35982954
[TBL] [Abstract][Full Text] [Related]
4. GRN is a prognostic biomarker and correlated with immune infiltration in glioma: A study based on TCGA data.
Xu SM; Xiao HY; Hu ZX; Zhong XF; Zeng YJ; Wu YX; Li D; Song T
Front Oncol; 2023; 13():1162983. PubMed ID: 37091137
[TBL] [Abstract][Full Text] [Related]
5. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
Tian QS; Zhang Q; Huang W
Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
[TBL] [Abstract][Full Text] [Related]
6. Development and validation a prognostic model based on natural killer T cells marker genes for predicting prognosis and characterizing immune status in glioblastoma through integrated analysis of single-cell and bulk RNA sequencing.
Hu J; Xu L; Fu W; Sun Y; Wang N; Zhang J; Yang C; Zhang X; Zhou Y; Wang R; Zhang H; Mou R; Du X; Li X; Hu S; Xie R
Funct Integr Genomics; 2023 Aug; 23(3):286. PubMed ID: 37650991
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Analysis of CD163 as a Prognostic Biomarker and Associated with Immune Infiltration in Glioblastoma Multiforme.
Li H; Wang D; Yi B; Cai H; Xi Z; Lou X; Li Z
Biomed Res Int; 2021; 2021():8357585. PubMed ID: 34395626
[TBL] [Abstract][Full Text] [Related]
8. A new prognostic model for glioblastoma multiforme based on coagulation-related genes.
Zhou M; Deng Y; Fu Y; Liang R; Liu Y; Liao Q
Transl Cancer Res; 2023 Oct; 12(10):2898-2910. PubMed ID: 37969372
[TBL] [Abstract][Full Text] [Related]
9. Identification of SEC61G as a Novel Prognostic Marker for Predicting Survival and Response to Therapies in Patients with Glioblastoma.
Liu B; Liu J; Liao Y; Jin C; Zhang Z; Zhao J; Liu K; Huang H; Cao H; Cheng Q
Med Sci Monit; 2019 May; 25():3624-3635. PubMed ID: 31094363
[TBL] [Abstract][Full Text] [Related]
10. CDC6 is up-regulated and a poor prognostic signature in glioblastoma multiforme.
Zhao H; Zhou X; Yuan G; Hou Z; Sun H; Zhai N; Huang B; Li X
Clin Transl Oncol; 2021 Mar; 23(3):565-571. PubMed ID: 32661826
[TBL] [Abstract][Full Text] [Related]
11. High Mobility Group Box 1 (HMGB1) Predicts Invasion and Poor Prognosis of Glioblastoma Multiforme via Activating AKT Signaling in an Autocrine Pathway.
Cheng P; Ma Y; Gao Z; Duan L
Med Sci Monit; 2018 Dec; 24():8916-8924. PubMed ID: 30531692
[TBL] [Abstract][Full Text] [Related]
12. A Pan-Cancer Analysis of the Oncogenic Role of
Yang D; Li H; Chen Y; Li C; Ren W; Huang Y
Front Genet; 2022; 13():906174. PubMed ID: 35910232
[No Abstract] [Full Text] [Related]
13. Dexamethasone-mediated oncogenicity in vitro and in an animal model of glioblastoma.
Luedi MM; Singh SK; Mosley JC; Hassan ISA; Hatami M; Gumin J; Andereggen L; Sulman EP; Lang FF; Stueber F; Fuller GN; Colen RR; Zinn PO
J Neurosurg; 2018 Dec; 129(6):1446-1455. PubMed ID: 29328002
[TBL] [Abstract][Full Text] [Related]
14. Fatty Acid Metabolic Signaling Pathway Alternation Predict Prognosis of Immune Checkpoint Inhibitors in Glioblastoma.
Liu R; Liang W; Hua Q; Wu L; Wang X; Li Q; Zhong F; Li B; Qiu Z
Front Immunol; 2022; 13():819515. PubMed ID: 35251000
[TBL] [Abstract][Full Text] [Related]
15. SAMSN1 is highly expressed and associated with a poor survival in glioblastoma multiforme.
Yan Y; Zhang L; Xu T; Zhou J; Qin R; Chen C; Zou Y; Fu D; Hu G; Chen J; Lu Y
PLoS One; 2013; 8(11):e81905. PubMed ID: 24278465
[TBL] [Abstract][Full Text] [Related]
16. Construction and Validation of an Immune-Related Risk Score Model for Survival Prediction in Glioblastoma.
Ren W; Jin W; Liang Z
Front Neurol; 2022; 13():832944. PubMed ID: 35370869
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of GBP1 predicts poor prognosis and promotes tumor growth in human glioblastoma multiforme.
Ji X; Zhu H; Dai X; Xi Y; Sheng Y; Gao C; Liu H; Xue Y; Liu J; Shi J; Zhang Y; Chen Y; Dai X; Li M; Wang A; Dong J
Cancer Biomark; 2019; 25(3):275-290. PubMed ID: 29991124
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of an inflammatory response-related prognostic model and immune infiltration analysis in glioblastoma.
Zhu W; Luo N; Li Q; Chen X; Li X; Fu M; Yang F; Chen Z; Zhang Y; Zhang Y; Peng X; Hu G
Ann Transl Med; 2023 Jan; 11(2):69. PubMed ID: 36819551
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of the prognosis and immune infiltrates for the BET protein family reveals the significance of BRD4 in glioblastoma multiforme.
Ye Y; Zhong W; Qian J; Zhang J; Xu T; Han R; Han J; Wang C; Song L; Zeng X; Wang H
Front Cell Dev Biol; 2023; 11():1042490. PubMed ID: 36711038
[No Abstract] [Full Text] [Related]
20. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
